Cyclerion Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cyclerion Therapeutics generated cash of -$21,245,000, which is more than the previous year. Cash used in financing activities reached the amount of $5,024,000 last year. Net change in cash is therefore -$5,811,000.
Cash Flow
| 2017 | -81.21M | -1.40M | 82.62M |
|---|---|---|---|
| 2018 | -97.50M | -3.43M | 100.94M |
| 2019 | -102.21M | -6.71M | 211.57M |
| 2020 | -72.49M | 18K | 28.09M |
| 2021 | -36.51M | 1.45M | 30.78M |
| 2022 | -40.61M | 0 | 29K |
| 2023 | -21.24M | 10.40M | 5.02M |
CYCN Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.38M | 53.96M | 58.23M | 102.62M | 0 | 0 | 0 |
Operating activities | |||||||
Net income | -5.26M | -44.07M | -51.64M | -77.80M | -123.00M | -115.25M | -93.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 0 | 65K | 472K | 2.29M | 2.7M | 1.52M | 1.74M |
Stock-based compensation expense | 1.06M | 6.25M | 9.61M | 14.99M | 19.63M | 0 | 9.49M |
| Deferred income tax benefit | 1.06M | 6.25M | 9.61M | 14.99M | 19.63M | 0 | 9.49M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 96K | 4K | 27K | 1.34M | -1.47M | 0 | 0 |
Inventories | 0 | 0 | 0 | -4.35M | -3.17M | 0 | 0 |
Accounts payable | -1.77M | 1.14M | 393K | -1.09M | -250K | 979K | 392K |
Cash generated by operating activities | -21.24M | -40.61M | -36.51M | -72.49M | -102.21M | -97.50M | -81.21M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -7K | -1.52M | -6.88M | -3.43M | -1.40M |
Acquisitions Net | 0 | 0 | 1.46M | 1.54M | 173K | 0 | 0 |
Cash generated by investing activities | 10.40M | 0 | 1.45M | 18K | -6.71M | -3.43M | -1.40M |
Financing activities | |||||||
Common Stock Issued | 5.02M | 29K | 30.50M | 24.25M | 175M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -3.50M | 0 | 0 | 0 |
Cash used in financing activities | 5.02M | 29K | 30.78M | 28.09M | 211.57M | 100.94M | 82.62M |
Net Change In Cash | -5.81M | -40.57M | -4.27M | -44.38M | 102.62M | 0 | 0 |
Cash at end of period | 7.57M | 13.38M | 53.96M | 58.23M | 102.62M | 0 | 0 |
| Data source | Data source | Data source | Data source | Data source |